A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas.

Trial Profile

A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary) ; Fluorouracil
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2011 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Results published in Annals of Surgery, according to a BioSante Pharmaceuticals media release.
    • 04 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top